Janet Brutschea Haugen

October 14, 2026

Goldman Sachs cuts NCR Voyix price target to $8. Goldman Sachs maintained a Neutral rating on NCR Voyix but lowered its price target to $8. This action follows the company's recent Q2 2026 earnings call. The new target is below the current average analyst estimate of $12.96, reflecting a cautious outlook from the firm.

October 5, 2026

Bentley Systems highlighted as AI beneficiary in engineering sector. Recent commentary positions Bentley Systems as a potential beneficiary of AI trends through deterministic engineering, distinguishing it from peers like Autodesk. This narrative provides context for the stock's current valuation, which sits near the lower end of its 52-week range with an average analyst target of $43.93. The focus on AI integration suggests investors are watching how the company leverages technology to maintain its market position.

October 17, 2026

West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.